Leonard Heffner Jr. MD
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Wake Forest University, Winston-Salem
- BS from Davidson College
Research
Focus
- Multiple myeloma, lymphoma, leukemia, Waldenstrms
Publications
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenstrm's macroglobulinemia.
Future Oncol Volume: 19 Page(s): 345 - 353
02/01/2023 Authors: Buske C; Tedeschi A; Trotman J; Garca-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS -
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Blood Cancer J Volume: 12 Page(s): 115
08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT -
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT -
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrm's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
J Clin Oncol Volume: 40 Page(s): 52 - 62
01/01/2022 Authors: Buske C; Tedeschi A; Trotman J; Garca-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS -
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Lancet Haematol Volume: 8 Page(s): e794 - e807
11/01/2021 Authors: Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A -
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
Blood Cancer Discov Volume: 2 Page(s): 600 - 615
11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC -
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood Volume: 137 Page(s): 3604 - 3615
07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT -
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood Volume: 137 Page(s): 2634 - 2645
05/13/2021 Authors: Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M -
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
JCO Oncol Pract Volume: 17 Page(s): e497 - e505
04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS -
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Am J Hematol Volume: 96 Page(s): E68 - E71
03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH -
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT -
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1928 - 1937
06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK -
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
J Clin Med Volume: 9
05/20/2020 Authors: Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F -
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Cancer Volume: 126 Page(s): 1235 - 1242
03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM -
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Blood Adv Volume: 4 Page(s): 449 - 457
02/11/2020 Authors: Jain N; Stock W; Zeidan A; Atallah E; McCloskey J; Heffner L; Tomlinson B; Bhatnagar B; Feingold J; Ungar D -
Daratumumab-associated hemophagocytic lymphohistiocytosis.
Ann Hematol Volume: 99 Page(s): 181 - 182
01/01/2020 Authors: Woods A; Wooten M; Thompson Heffner L; Waller E -
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Clin Cancer Res Volume: 25 Page(s): 6986 - 6994
12/01/2019 Authors: Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT -
ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
Hematol Rep Volume: 11 Page(s): 8395
11/29/2019 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangaonkar A; Kota VK -
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood Cancer J Volume: 9 Page(s): 94
11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J -
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica Volume: 104 Page(s): 2258 - 2264
11/01/2019 Authors: Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre SE; Choi M; Furman RR; Heffner L; Barr PM; Eradat H -
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Blood Adv Volume: 3 Page(s): 3033 - 3037
10/22/2019 Authors: Gkbuget N; Kantarjian HM; Brggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M -
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Volume: 125 Page(s): 2991 - 3000
09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S -
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200.
J Immunother Cancer Volume: 7 Page(s): 227
08/23/2019 Authors: Mahadevan D; Lanasa MC; Farber C; Pandey M; Whelden M; Faas SJ; Ulery T; Kukreja A; Li L; Bedrosian CL -
Daratumumab in multiple myeloma.
Cancer Volume: 125 Page(s): 2364 - 2382
07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S -
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Br J Haematol Volume: 185 Page(s): 961 - 966
06/01/2019 Authors: Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M -
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 372 - 380
06/01/2019 Authors: Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F -
Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?
J Oncol Pract Volume: 15 Page(s): 315 - 320
06/01/2019 Authors: Roberts MMSc D; Langston AA; Heffner LT -
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Leukemia Volume: 33 Page(s): 1291 - 1296
05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL -
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer Volume: 125 Page(s): 416 - 423
02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK -
Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Cancer Volume: 125 Page(s): 185 - 193
01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR -
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J Volume: 9 Page(s): 3
01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT -
Outcomes and Clinical Features of Patients with 1q+Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone
Volume: 132
11/29/2018 Authors: Schmidt TM; Joseph N; Odikadze L; Heffner L; Hofmeister CC; Dhodapkar MV; Gupta VA; Boise LH; Jaye DL; Lonial S -
Safety and Efficacy of Evomela in Myeloma Autotransplants
Volume: 132
11/29/2018 Authors: Amelsberg K; Joseph N; Langston A; Kaufman JL; Hofmeister CC; Waller EK; Graiser M; Larocco R; Heffner L; Dhodapkar MV -
Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma
Volume: 132
11/29/2018 Authors: Joseph N; Gupta VA; Hofmeister CC; Gleason C; Heffner L; Boise LH; Kaufman JL; Dhodapkar MV; Lonialand S; Nooka AK -
Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
Volume: 132
11/29/2018 Authors: Joseph N; Gupta VA; Hofmeister CC; Gleason C; Heffner L; Boise LH; Kaufman JL; Dhodapkar MV; Lonial S; Nooka AK -
Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study
Volume: 132
11/29/2018 Authors: Caimi P; Kahl BS; Hamadani M; Carlo-Stella C; He S; Ungar D; Feingold J; Ardeshna KM; Radford J; Solh M -
Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
Volume: 132
11/29/2018 Authors: Odikadze L; Joseph N; Schmidt TM; Heffner L; Hofmeister CC; Dhodapkar MV; Gupta VA; Boise LH; Jaye DL; Lonial S -
Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses
Volume: 132
11/29/2018 Authors: Hofmeister CC; Sborov DW; Viola D; Dona A; Nuovo GJ; Benson DM; Lonial S; Kaufman JL; Nooka AK; Heffner L -
Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma
Volume: 132
11/29/2018 Authors: Matulis SM; Gupta VA; Brown I; Keats JJ; Secrist P; Cidado J; Tron AE; Neri P; Bahlis N; Kaufman JL -
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 132
11/29/2018 Authors: Bernal-Mizrachi L; Cole CE; Heffner L; Nooka AK; Vij R; Kelkar N; Sridhar A; Cinar M; Chen Z; Chang Z -
Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Volume: 132
11/29/2018 Authors: Radford J; Kahl BS; Hamadani M; Carlo-Stella C; Caimi P; Ardeshna KM; Feingold J; He S; Reid E; Solh M -
TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
Volume: 93 Page(s): E51 - E51
09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M -
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Volume: 36
05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK -
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood Volume: 131 Page(s): 1704 - 1711
04/12/2018 Authors: Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T -
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
Leukemia Volume: 32 Page(s): 562 - 565
02/01/2018 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Duell J; Bargou RC; Holland C; Benjamin JE -
Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Volume: 130
12/07/2017 Authors: Jain N; Klisovic RB; Stock W; Ungar D; Zeidan AM; Atallah E; McCloskey J; Heffner L; Tomlinson B; Kantarjian HM -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Volume: 130
12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A -
Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths
Volume: 130
12/07/2017 Authors: Kota V; Arellano ML; Kharkhanis P; Bolds S; Caprara CR; Simon KS; Debragga S; Gaddh M; Bernal-Mizrachi L; Heffner L -
Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia
Volume: 130
12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK -
Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
Volume: 130
12/07/2017 Authors: Kong JH; Winton EF; Heffner L; Gaddh M; Hill B; Arellano ML; El-Rassi F; Kim A; Kota V -
Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy
Volume: 130
12/07/2017 Authors: Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre S; Choi M; Furman RR; Heffner L; Barr PM; Eradat H -
Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma
Volume: 130
12/07/2017 Authors: Kahl BS; Hamadani M; Caimi P; Carlo-Stella C; Reid E; Feingold J; Ardeshna KM; Radford J; Solh MM; Chung K-Y -
Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)
Volume: 130
12/07/2017 Authors: Wierda WG; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Jones J; Zhou L; Verdugo M -
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): e71 - e73
12/01/2017 Authors: Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ -
Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
Hematol Rep Volume: 9 Page(s): 7083
09/26/2017 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangoankar A; Kota VK -
Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE (TM))
Volume: 40 Page(s): 119 - 119
09/01/2017 Authors: Buske C; Trotman J; Tedeschi A; Matous J; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT -
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Cancer Volume: 123 Page(s): 2482 - 2488
07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A -
PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTROM MACROGLOBULINEMIA (WM)
Volume: 102 Page(s): 510 - 510
06/26/2017 Authors: Trotman J; Dimopoulos MA; Tedeschi A; Matous JV; Heffner LT; Shustik C; Garcia-Sanz R; Castillo JJ; Leblond V; Kastritis E -
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Clin Cancer Res Volume: 23 Page(s): 2400 - 2404
05/15/2017 Authors: Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ -
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
CLINICAL CANCER RESEARCH Volume: 23 Page(s): 2400 - 2404
05/15/2017 Authors: Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ -
Ibrutinib for patients with rituximab-refractory Waldenstrm's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Lancet Oncol Volume: 18 Page(s): 241 - 250
02/01/2017 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT -
Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
Volume: 128
12/02/2016 Authors: Kong JH; Khoury HJ; Winton EF; Heffner LT; Gaddh M; Arellano M; El-Rassi F; Kim AS; Jillella A; Bodo I -
A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States
Volume: 128
12/02/2016 Authors: Kota V; Karkhanis P; Sharma R; Bolds S; Sitchenko K; Shrestha A; Jonnalagadda V; Gaddh M; Bernal-Mizrachi L; Heffner LT -
A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States
Volume: 128
12/02/2016 Authors: Jillella A; Karkhanis P; Sharma R; Bolds S; Shrestha A; Sitchenko K; Jonnalagadda V; Gaddh M; Bernal-Mizrachi L; Heffner LT -
Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma
Volume: 128
12/02/2016 Authors: Kelly KR; Siegel DS; Chanan-Khan AA; Somlo G; Heffner LT; Jagannath S; Zimmerman T; Munshi NC; Madan S; Mohrbacher A -
a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Volume: 128
12/02/2016 Authors: Maddocks KJ; Cohen JB; Huang Y; Christian BA; Benson DM; Jones J; Flowers C; Heffner LT; Jenkins C; Sexton J -
Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib
Volume: 128
12/02/2016 Authors: Jones J; Choi MY; Mato AR; Furman RR; Davids MS; Heffner LT; Cheson BD; Lamanna N; Barr PM; Eradat H -
Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE (TM))
Volume: 39 Page(s): 119 - 119
10/01/2016 Authors: Buske C; Trotman J; Tedeschi A; Matous J; Macdonald D; Tam C; Toumilhac O; Ma S; Oriol A; Heffner LT -
DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
Volume: 101 Page(s): 675 - 676
06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L -
SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)
Volume: 101 Page(s): 256 - 257
06/01/2016 Authors: Dimopoulos M; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner L -
VENETOCLAX IS ACTIVE IN CLL PATIENTS WHO HAVE RELAPSED AFTER OR ARE REFRACTORY TO IBRUTINIB OR IDELALISIB
Volume: 101 Page(s): 231 - 232
06/01/2016 Authors: Coutre S; Wierda W; Choi M; Davids MS; Cheson BD; Furman RR; Lamanna N; Barr PM; Eradat H; Halwani A -
Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
Volume: 34
05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT -
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
Volume: 34
05/20/2016 Authors: Chung KY; Hamadani M; Kahl BS; Heffner LT; Caimi PF; Feingold JM; O'Connor OA -
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
Volume: 34
05/20/2016 Authors: Jones JA; Wierda WG; Choi MY; Davids MS; Cheson BD; Furman RR; Lamanna N; Barr PM; Eradat HA; Halwani AS -
Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenstrom's macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE (TM))
Volume: 173 Page(s): 82 - 82
04/01/2016 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT -
Early Allogeneic Stem Cell Transplantation Appears to Improve Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi-Institutional Review
Volume: 22 Page(s): S202 - S202
03/01/2016 Authors: Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella AP; Arellano M; Heffner LT; Erba HP -
Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma
Volume: 126
12/03/2015 Authors: Kota VK; Hathaway AR; Shah BD; Peker D; Zhang L; Jaye DL; Arellano M; Khoury HJ; Jillella AP; Winton EF -
Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience
Volume: 126
12/03/2015 Authors: Zeichner SB; Gleason S; Antun AG; Langston A; Heffner LT; Kota VK; Gaddh M; Arellano M -
Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA
Volume: 126
12/03/2015 Authors: Jillella A; Arellano M; Bashey A; Vidito SI; Stuart RK; Leung C; Sitchenko K; Gaddh M; Heffner LT; Kolhe RB -
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
Volume: 126
12/03/2015 Authors: Khoury HJ; Heffner LT; Arellano M; Jillella AP; Kota VK; Winton EF -
Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review
Volume: 126
12/03/2015 Authors: Borate U; Hathaway AR; Peker D; Jackson BE; Kota VK; Shah BD; Zhang L; Jillella A; Arellano M; Heffner LT -
Plasma Vincristine Levels Are 100-Fold Higher with Marqibo (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Volume: 126
12/03/2015 Authors: Wang ES; Schiller GJ; Heffner LT; Stock W; Rao AV; Roboz GJ; Westervelt P; Wieduwilt MJ; Yang J; Prasad L -
Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenstrom's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE (TM))
Volume: 126
12/03/2015 Authors: Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT -
A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
Volume: 126
12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA -
Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
Volume: 126
12/03/2015 Authors: Thomas SK; Harb WA; Beck JT; Nashat G; Palomba ML; Ansell SM; Eradat H; Libby EN; Advani RH; Hajdenberg J -
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Volume: 171 Page(s): 539 - 546
11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ -
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma
British Journal of Haematology Volume: 171 Page(s): 539 - 546
11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ -
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A -
INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB
Volume: 100 Page(s): 30 - 30
06/01/2015 Authors: Topp MS; Goekbuget N; O'Brien S; Stein A; Jia C; Forman SJ; Bargou R; Fielding AK; Heffner LT; Larson RA -
RETREATMENT WITH BLINATUMOMAB AFTER CD19-POSITIVE RELAPSE: EXPERIENCE FROM 3 TRIALS IN PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)
Volume: 100 Page(s): 31 - 32
06/01/2015 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Bargou R; Jia C; Benjamin J; Litzow MR -
Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
Volume: 33
05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S -
A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
Volume: 33
05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA -
Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.
Volume: 33
05/20/2015 Authors: Kantarjian H; Goekbuget N; O'Brien SM; Stein AS; Jia C; Forman SJ; Bargou RC; Fielding AK; Heffner LT; Larson RA -
Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).
Volume: 33
05/20/2015 Authors: Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett TM; Bargou RC; Holland C; Benjamin J; Litzow MR -
A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom's macroglobulinemia (PCYC-1127-CA).
Volume: 33
05/20/2015 Authors: Dimopoulos MA; Leleu X; Matous J; MacDonald D; Trotman J; Oriol A; Shustik C; Tedeschi A; Garcia-Sanz R; Heffner LT -
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
Cancer Volume: 121 Page(s): 872 - 875
03/15/2015 Authors: El Rassi F; Bergsagel JD; Arellano M; Gaddh M; Jillella A; Kota V; Heffner LT; Winton EF; Khoury HJ -
Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
CANCER Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol Volume: 16 Page(s): 57 - 66
01/01/2015 Authors: Topp MS; Gkbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA -
Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma
Volume: 124
12/06/2014 Authors: Valla K; Kaufman JL; Gleason C; Boise LH; Heffner LT; Manubolu S; Bisht AS; Watson M; Nooka AK; Lonial S -
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Volume: 124
12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW -
Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
BLOOD Volume: 124
12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S -
Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib
BLOOD Volume: 124
12/06/2014 Authors: Kelly KR; Chanan-Khan A; Heffner LT; Somlo G; Siegel DS; Zimmerman T; Karnad A; Munshi NC; Jagannath S; Greenberg AL -
An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE (R) Antibody Construct Blinatumomab
BLOOD Volume: 124
12/06/2014 Authors: Goekbuget N; Kantarjian H; Brueggemann M; Stein A; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M -
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Blood Volume: 124 Page(s): 2498 - 2506
10/16/2014 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blad J; Fermand J-P; Hassoun H; Heffner L; Kukreti V -
Cardiac plasmacytoma: a rare clinical entity.
Tex Heart Inst J Volume: 41 Page(s): 554 - 557
10/01/2014 Authors: Vrettou A-R; Heffner LT; Rossi PJ; Clements SD -
Early Blast Phase Transformation In Chronic Phase Chronic Myeloid Leukemia: Is Flow Cytometry The Missing Link?
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S136 - S137
09/01/2014 Authors: El Rassi F; Arellano M; Winton E; Heffner L; Gaddh M; Khoury HJ -
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
South Med J Volume: 107 Page(s): 497 - 500
08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A -
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
Leuk Lymphoma Volume: 55 Page(s): 1498 - 1500
07/01/2014 Authors: Mitri Z; Siddiqui MT; El Rassi F; Holden JT; Heffner LT; Langston A; Waller EK; Winton E; McLemore M; Bernal-Mizrachi L -
Prepregnancy body mass index and risk of preterm birth: association heterogeneity by preterm subgroups.
BMC Pregnancy Childbirth Volume: 14 Page(s): 153
04/30/2014 Authors: Parker MG; Ouyang F; Pearson C; Gillman MW; Belfort MB; Hong X; Wang G; Heffner L; Zuckerman B; Wang X -
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Leukemia Volume: 28 Page(s): 690 - 693
03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S -
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
Leukemia Volume: 28 Page(s): 690 - 693
01/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S -
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT -
Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S -
Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data
Volume: 122
11/15/2013 Authors: Nelson S; Boise LH; Kaufman JL; Heffner LT; Shah NN; Lechowicz MJ; Lonial S; Nooka AK -
Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
Volume: 122
11/15/2013 Authors: Kelly KR; Chanan-Khan A; Somlo G; Heffner LT; Siegel DS; Zimmerman TM; Jagannath S; Munshi NC; Lonial S; Roy V -
Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RADoo1) As Primary Therapy In Waldenstrom's Macroglobulinemia
Volume: 122
11/15/2013 Authors: Treon SP; Tripsas CK; Meid K; Patterson C; Heffner LT; Eradat H; Gregory SA; Thomas SK; Advani RH; Baz R -
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
Cancer Volume: 119 Page(s): 3784 - 3787
11/01/2013 Authors: Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT -
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 430 - 434
08/01/2013 Authors: Wetzler M; Thomas DA; Wang ES; Shepard R; Ford LA; Heffner TL; Parekh S; Andreeff M; O'Brien S; Kantarjian HM -
PHASE I STUDY OF THE COMBINATION OF CARFILZOMIB AND PANOBINOSTAT FOR PATIENTS WITH RELAPSED AND REFRACTORY MYELOMA: A MULTICENTER MMRC CLINICAL TRIAL
Volume: 98 Page(s): 322 - 323
06/12/2013 Authors: Kaufman J; Zimmerman T; Jakubowiak A; Rosenbaum C; Lewis C; Harvey D; Nooka A; Heffner L; Lonial S -
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL -
Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis
Volume: 31
05/20/2013 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blade J; Fermand J-P; Hassoun H; Heffner L; Pei L -
Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.
Cancer Volume: 119 Page(s): 1186 - 1194
03/15/2013 Authors: Lamanna N; Heffner LT; Kalaycio M; Schiller G; Coutre S; Moore J; Seiter K; Maslak P; Panageas K; Golde D -
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
J Clin Oncol Volume: 31 Page(s): 676 - 683
02/20/2013 Authors: O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
Volume: 120
11/16/2012 Authors: Kaufman JL; Shah JJ; Laubach JP; Mitchell AR; Sharp C; Lewis C; Harvey RD; Gleason C; Casbourne D; Nooka AK -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
Volume: 120
11/16/2012 Authors: Kaufman JL; Shah JJ; Laubach JP; Mitchell AR; Sharp C; Lewis C; Harvey RD; Gleason C; Casbourne D; Nooka AK -
BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity
Volume: 120
11/16/2012 Authors: Heffner LT; Jagannath S; Zimmerman TM; Lee KP; Rosenblatt J; Lonial S; Lutz RJ; Czeloth N; Osterroth F; Ruehle M -
Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia
Volume: 120
11/16/2012 Authors: El Rassi F; Arellano M; Heffner LT; Waller EK; Winton EF; Ward K; Khoury HJ -
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Cancer Volume: 118 Page(s): 5278 - 5282
11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ -
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
Br J Haematol Volume: 158 Page(s): 608 - 614
09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L -
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Cancer Volume: 118 Page(s): 3538 - 3548
07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT -
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L -
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S -
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Leuk Lymphoma Volume: 53 Page(s): 725 - 727
04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M -
Managing chronic myeloid leukemia: a coordinated team care perspective.
Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 88 - 93
04/01/2012 Authors: Holloway S; Lord K; Bethelmie-Bryan B; Shepard MW; Neely J; McLemore M; Reddy SK; Montero A; Jonas WS; Gladney SP -
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
Cancer Volume: 118 Page(s): 428 - 433
01/15/2012 Authors: Arellano M; Winton E; Pan L; Lima L; Tighiouart M; Bhalla K; Heffner LT; Neely J; Hutcherson D; McLemore M -
Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
Volume: 118 Page(s): 707 - 708
11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT -
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Volume: 118 Page(s): 142 - 143
11/18/2011 Authors: Jagannath S; Chanan-Khan A; Heffner LT; Avigan D; Zimmerman TM; Lonial S; Lutz RJ; Engling A; Uherek C; Osterroth F -
Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia
Volume: 118 Page(s): 1273 - 1274
11/18/2011 Authors: Treon SP; Tripsas CK; Ioakimidis L; Warren D; Patterson C; Heffner L; Eradat H; Gregory SA; Thomas S; Advani R -
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
QJM Volume: 104 Page(s): 957 - 970
11/01/2011 Authors: Dubrey SW; Reece DE; Sanchorawala V; Hegenbart U; Merlini G; Palladini G; Fermand J-P; Vescio RA; Blad J; Heffner LT -
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 427 - 432
10/01/2011 Authors: Arellano M; Bernal-Mizrachi L; Pan L; Tighiouart M; Souza L; Guo X; McLemore M; Lima L; Sunay S; Heffner LT -
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Blood Volume: 118 Page(s): 865 - 873
07/28/2011 Authors: Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Blad J; Fermand J-P; Hassoun H; Heffner L; Vescio RA -
A new formulation of vincristine for acute lymphoblastic leukemia.
Clin Adv Hematol Oncol Volume: 9 Page(s): 314 - 316
04/01/2011 Authors: Heffner L -
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
Cancer Volume: 117 Page(s): 1245 - 1252
03/15/2011 Authors: Lima L; Bernal-Mizrachi L; Saxe D; Mann KP; Tighiouart M; Arellano M; Heffner L; McLemore M; Langston A; Winton E -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
Volume: 116 Page(s): 1251 - 1251
11/19/2010 Authors: Kaufman JL; Shah JJ; Laubach JP; Heffner L; Francis D; Harvey RD; Lewis C; Tighiouart M; Richardson P; Orlowski RZ -
First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)
Volume: 116 Page(s): 1024 - 1024
11/19/2010 Authors: Mahadevan D; Lanasa MC; Whelden M; Faas SJ; Ulery TL; Kukreja A; Li L; Bedrosian CL; Heffner LT -
Margibo (R) (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies.
Volume: 116 Page(s): 885 - 885
11/19/2010 Authors: O'Brien S; Thomas DA; Heffner LT; Stock W; Messerschmidt GL; Hagey A; Deitcher SR; Kantarjian H -
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Volume: 116 Page(s): 1262 - 1262
11/19/2010 Authors: Jagannath S; Chanan-Khan AA; Heffner LT; Avigan D; Lutz RJ; Uherek C; Osterroth F; Ruehle M; Haeder T; Niemann G -
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD -
Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Cancer Volume: 116 Page(s): 3143 - 3151
07/01/2010 Authors: Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S -
Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Arellano ML; Pan L; Lima L; Tighiouart M; Heffner LT; Langston AA; McLemore M; Neely J; Winton EF; Khoury HJ -
A PHASE I/II STUDY TARGETING THE IMMUNOSUPPRESSIVE MOLECULE CD200 IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING THE HUMANIZED ANTIBODY SAMALIZUMAB
Volume: 21 Page(s): 43 - 43
01/01/2010 Authors: Mahadevan D; Lanasa MC; Farber CM; Whelden M; Faas SJ; Ulery T; Kukreja A; Li L; Bedrosian CL; Heffner LT -
Clinical value of minor responses after 4 doses of rituximab in Waldenstrm macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
Br J Haematol Volume: 147 Page(s): 677 - 680
12/01/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV -
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Cancer Volume: 115 Page(s): 5490 - 5498
12/01/2009 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B -
Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
Volume: 114 Page(s): 1496 - 1496
11/20/2009 Authors: Nooka AK; Kaufman JL; Heffner LT; Gleason CL; Lonial S -
Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo (R)) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.
Volume: 114 Page(s): 1200 - 1201
11/20/2009 Authors: O'Brien S; Schiller G; Damon LE; Lister J; Ravandi F; Douer D; Masood A; Ben-Yehuda D; Rowe JM; Goekbuget N -
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.
Volume: 114 Page(s): 738 - 739
11/20/2009 Authors: Chanan-Khan AA; Jagannath S; Heffner LT; Avigan D; Lee KP; Lutz RJ; Haeder T; Ruehle M; Uherek C; Wartenberg-Demand AB -
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
J Clin Oncol Volume: 27 Page(s): 3518 - 3525
07/20/2009 Authors: Richardson PG; Xie W; Mitsiades C; Chanan-Khan AA; Lonial S; Hassoun H; Avigan DE; Oaklander AL; Kuter DJ; Wen PY -
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
Volume: 27
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E -
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML)
Volume: 27
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ -
A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines
Volume: 27
05/20/2009 Authors: Heffner LT; Damon LE; Larson ML; Schiller G; Stock W; Kantarjian HM; Lu B; Imperiale SM; O'Brien S -
Long-lasting responses after four doses of rituximab in Waldenstrom's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial
Volume: 27
05/20/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV -
Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
J Clin Oncol Volume: 27 Page(s): 7064
05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E -
Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
J Clin Oncol Volume: 27 Page(s): 7070
05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ -
A phase II study of the tolerability and activity of weekly vincristine sulfate liposomes injection (VSLI) in adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second relapse or progressing following two antileukemia treatment lines.
J Clin Oncol Volume: 27 Page(s): 7046
05/20/2009 Authors: Heffner LT; Damon LE; Larson ML; Schiller G; Stock W; Kantarjian HM; Lu B; Imperiale SM; O'Brien S -
Long-lasting responses after four doses of rituximab in Waldenstrm's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
J Clin Oncol Volume: 27 Page(s): 8513
05/20/2009 Authors: Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV -
A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT -
A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
Volume: 112 Page(s): 1144 - 1145
11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK -
Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
Volume: 112 Page(s): 1247 - 1247
11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R -
Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis
Volume: 112 Page(s): 1062 - 1062
11/16/2008 Authors: Langston A; Neely J; Heffner L; Griffith D; Arellano M; Esper G; McLemore ML; Ziegler T; Kempton C; Sinha R -
Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo (TM)) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Volume: 112 Page(s): 1008 - 1008
11/16/2008 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner L; Hirabayashi S; Lu B; Deitcher SR; O'Brien S -
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP -
Staging in Multiple Myeloma
Page(s): 3 - 7
01/01/2008 Authors: Heffner LT -
A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
Volume: 110 Page(s): 288A - 289A
11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
Volume: 110 Page(s): 1055A - 1055A
11/16/2007 Authors: Kaufman JL; Gleason C; Heffner L; Lonial S -
Safety and efficacy of marqibo (vincristine sulfate liposomes injection, OPTISOME (TM)) in for the treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL)
Volume: 110 Page(s): 263A - 263A
11/16/2007 Authors: Thomas DA; Kantarjian HM; Stock W; Heffner L; Tredinnick A; Lu B; Choy GS; Deitcher SR; O'Brien SM -
Bortezomib,thalidomide and dexamethasone as induction
Volume: 92 Page(s): 181 - 181
06/01/2007 Authors: Kaufman JL; Gleason C; Heffner LT; Langston AA; Waller EK; Lonial S -
Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
Volume: 108 Page(s): 554A - 554A
11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ -
Benefits of CHOP-14 followed by transplantation in patients with peripheral T-cell lymphoma.
Volume: 108 Page(s): 254B - 254B
11/16/2006 Authors: Abouyabis AN; Lechowicz M; Mann K; Heffner LT; Winton E; Bucur S; Flowers CR -
Deep venous thromboses associated with peripherally inserted central catheters in patients with hematological malignancies.
Volume: 108 Page(s): 226B - 226B
11/16/2006 Authors: Tran H; Chamsuddin A; Winton EF; Heffner L; Langston A; Waller N; Arellano M; Khoury HJ -
Phase I trial of sphingosomal vincristine (SV, Marqibo (R)) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL).
Volume: 108 Page(s): 214B - 214B
11/16/2006 Authors: Thomas DA; Kantaijian HM; Heffner L; Stock W; Garcia-Manero G; Faderl S; Ferrajoli A; Giles F; Wierda W; Ravandi-Kashani F -
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK -
Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study.
Volume: 24 Page(s): 423S - 423S
06/20/2006 Authors: Anderson K; Richardson P; Chanan-Khan A; Schlossman R; Munshi N; Oaklander A; Heffner L; Hassoun H; Avigan D; Amato A -
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Cancer Volume: 106 Page(s): 2171 - 2180
05/15/2006 Authors: Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S -
Multiple myeloma (MM) polyneuropathy before and after initial chemotherapy with single-agent bortezomib
Volume: 60 Page(s): S94 - S94
01/01/2006 Authors: Oaklander AL; Richardson PG; Briemberg H; Anderson KC; Wen P; Chan-Khan AA; Schlossman RL; Munshi NC; Heffner LT; Hassoun H -
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood Volume: 106 Page(s): 3777 - 3784
12/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Francis D; Giusti S; Torre C -
Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
Volume: 106 Page(s): 237B - 237B
11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E -
Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
Volume: 106 Page(s): 210B - 210B
11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E -
Prognostic significance of early peripheral blood blasts clearance following induction chemotherapy for adult acute myeloid leukemia.
Volume: 106 Page(s): 236B - 236B
11/16/2005 Authors: Pakkala S; Winton E; Langston A; Heffner LT; Khoury HJ -
Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity.
Volume: 23 Page(s): 587S - 587S
06/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Barlogie B; Heffner LT; Anderson KC -
A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL.
Volume: 23 Page(s): 564S - 564S
06/01/2005 Authors: Weiss MA; Heffner L; Lamanna N; Kalaycio M; Schiller G; Coutre S; Maslak P; Jurcic J; Panageas K; Scheinberg DA -
A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 104 Page(s): 502A - 502A
11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ -
Retrospective review of therapy with reduced dose rasburicase in adults with hyperuricemia associated with malignancy
Volume: 10 Page(s): 104 - 104
02/01/2004 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Shayani S; Barreras AM; Bucur SZ; Heffner LT; Langston AA -
Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma.
Volume: 102 Page(s): 447A - 447A
11/16/2003 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Francis D; Lehman M; Torre C; Barlogie B; Berenson JR; Singhal S -
A phase I study of dose escalated cytarabine in combination with a modified ESHAP-like regimen, paclitaxel, and vinorelbine (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 102 Page(s): 293B - 293B
11/16/2003 Authors: Lonial S; Tanner A; Langston AA; Redei I; Heffner LT; Bucur SZ; Hutcherson D; Winton E; Waller EK -
Early autologous transplantation for mantle cell lymphoma may improve long term disease-free survival.
Volume: 102 Page(s): 734A - 735A
11/16/2003 Authors: Murali S; Lonial S; Redei I; Smith K; Waller EK; Heffner LT; Bucur S; Winton E; Manion K; Langston A -
A phase I trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 102 Page(s): 333B - 333B
11/16/2003 Authors: Langston AA; Tanner A; Lonial S; Heffner LT; Smith K; Bucur S; Waller EK; Redei I; Winton E -
Signal transduction and myeloma: new targets, new hope.
Cancer Biol Ther Volume: 2 Page(s): 310 - 319
01/01/2003 Authors: Lonial S; Waller EK; Simons JW; Heffner LT -
Breakthroughs in the management of multiple myeloma.
Drugs Volume: 63 Page(s): 1621 - 1636
01/01/2003 Authors: Heffner LT; Lonial S -
Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
Volume: 100 Page(s): 178A - 178A
11/16/2002 Authors: Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S -
CD34 selection of peripheral blood progenitor cells for autologous transplant in myeloma and amyloidosis is associated with an increased risk of post-transplant varicella Zoster.
BLOOD Volume: 98 Page(s): 392A - 392A
11/16/2001 Authors: Smith KJ; Hamilton ES; Waller EK; Langston AA; Redei I; Lonial S; Heffner LT -
Non-fatal Veno-Occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin).
BLOOD Volume: 98 Page(s): 201B - 202B
11/16/2001 Authors: Langston AA; Feinstein B; Hutcherson D; Heffner LT; Redei I; Smith K; Lonial S; Bucur S; Jones A; Waller EK -
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Leuk Lymphoma Volume: 36 Page(s): 497 - 502
02/01/2000 Authors: Lonial S; Jones TW; Devine S; Winton EF; Heffner LT; Smith KJ; Yeager AM; Waller EK -
Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
BLOOD Volume: 94 Page(s): 233B - 233B
11/15/1999 Authors: Lonial S; Langston AA; Bhalla K; Smith KJ; Heffner LT; Bucur S; Hutcherson DA; Winton EF -
Autologous peripheral blood stem cell (PBSC) transplantation in AML: Outcome and flow cytometric analysis of the PBSC product.
BLOOD Volume: 94 Page(s): 398B - 398B
11/15/1999 Authors: Bucur SZ; Heffner LT; Langston AA; Redei J; Waller EK; Winton EF; Holden JT; Smith KJ -
Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation
Cancer Research Therapy and Control Volume: 5 Page(s): 221 - 228
11/25/1998 Authors: Zeder K; Waller EK; Redei I; Gerard Connaghan D; Fleming WH; Geller RB; Heffner LT; Hillyer CD; Holden J; Holland K -
Phase II study of PSC 833 (PSC) and vad chemotherapy in patients with VAD-refractory multiple myeloma (MM).
BLOOD Volume: 92 Page(s): 105A - 105A
11/15/1998 Authors: Case DC; Jain V; Stiff P; Jansen J; Stewart AK; Shurafa M; Hussein M; Heffner LT; Irwin D; Greipp P -
Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Bone Marrow Transplant Volume: 20 Page(s): 219 - 225
08/01/1997 Authors: Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I -
Presence of minimal residual disease (MRD) in acute myelogenous leukemia (AML) patients preallogeneic bone marrow transplantation (BMT) is associated with a lower relapse-free survival (RFS).
EXPERIMENTAL HEMATOLOGY Volume: 25 Page(s): 621 - 621
08/01/1997 Authors: Holland HK; Bray RA; OToole K; Holden JT; Connaghan DG; Heffner LT; Waller EK; Winton EF; Yeager AM -
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Biol Blood Marrow Transplant Volume: 3 Page(s): 25 - 33
04/01/1997 Authors: Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT -
Long term follow-up of edelfosine purging for autologous bone marrow transplantation (ABMT) in acute leukemia.
EXPERIMENTAL HEMATOLOGY Volume: 24 Page(s): 615 - 615
08/01/1996 Authors: Vogler WR; Berdel WE; Winton EF; Gordon DS; Geller RB; Heffner LT; Brochstein JA; Beveridge RA; Dalton WS; Miller KB -
Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
J Clin Oncol Volume: 14 Page(s): 1156 - 1164
04/01/1996 Authors: Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR -
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Bone Marrow Transplant Volume: 17 Page(s): 225 - 230
02/01/1996 Authors: Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB -
High dose cyclophosphamide, fractionated total body irradiation with involved field irradiation and autologous bone marrow transplantation in malignant lymphoma.
Leuk Lymphoma Volume: 20 Page(s): 249 - 257
01/01/1996 Authors: Tirona MR; Gordon DS; Crocker I; Eley JW; York R; Heffner LT; Winton EF; Vogler WR -
Evaluation of supportive care guidelines for monitoring breast cancer bone marrow transplant (BMT) patients in the outpatient setting.
BLOOD Volume: 86 Page(s): 838 - 838
11/15/1995 Authors: Miyahara TT; Dix SP; Devine SM; Holland HK; Connaghan DG; Fleming WH; Geller RB; Heffner LT; Hillyer CD; Waller EK -
Tacrolimus (FK506) combined with methotrexate (MTX) is effective in preventing acute graft versus host disease (AGVHD) following related donor allogeneic bone marrow transplantation (BMT).
BLOOD Volume: 86 Page(s): 1569 - 1569
11/15/1995 Authors: Devine SM; Geller RB; Dix SP; Connaghan DG; Fleming WH; Heffner LT; Hillyer CD; Holland HK; Waller EK; Winton EF -
Transplantation of HLA-identical positively selected CD34+ cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation
BLOOD Volume: 86 Page(s): 1543 - 1543
11/15/1995 Authors: Holland HK; Bray AM; Geller RB; Devine SM; McCollum J; Connaghan DG; Fleming WH; Heffner LT; Hillyer C; Waller EK -
Risk factors for severe acute renal failure (ARF) after matched unrelated donor transplantation (MUDT).
BLOOD Volume: 86 Page(s): 1552 - 1552
11/15/1995 Authors: Redei S; Geller RB; Devine S; OToole K; Persons L; Holland HK; Connaghan G; Fleming WH; Heffner LT; Hillyer C -
CRL-1336: First of a novel class of drugs used to reverse multidrug resistance (MDR1) gene expression in leukemia.
Volume: 86 Page(s): 2069 - 2069
11/15/1995 Authors: Shuster MW; Wei LX; Schulman P; Kolitz J; Buchbinder A; Allen S; Lichtman SM; Geller RB; Devine SM; Heffner LT -
Pixy-321 in combination with high dose cytarabine end mitoxantrone in poor prognosis acute myeloid leukemia (AML).
BLOOD Volume: 86 Page(s): 2068 - 2068
11/15/1995 Authors: Feldman E; Geller RB; Seiter K; Heffner L; Stuart R; Bhalla K -
BONE-MARROW TRANSPLANTATION (BMT) FOR INDOLENT LYMPHOMA UTILIZING BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY) AND ETOPOSIDE (E) FOLLOWED BY MAINTENANCE ALPHA-INTERFERON (IF) - 2-YEAR FOLLOW-UP RESULTS
BLOOD Volume: 84 Page(s): A209 - A209
11/15/1994 Authors: HOLLAND HK; HEFFNER LT; GELLER RB; DEVINE SM; HILLYER CD; WINTON EF; SARAL R; WINGARD JR -
SIMULTANEOUS ADMINISTRATION OF INTERLEUKEN-6 (RHIL-6) AND NEUPOGEN(R) (RHG-CSF) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR BREAST-CANCER (BCA)
BLOOD Volume: 84 Page(s): A89 - A89
11/15/1994 Authors: DEVINE SM; WINTON EF; HOLLAND HK; GELLER RB; HEFFNER LT; HILLYER CD; MORRIS LE; RODEY GE; BEVERIDGE R; LYNCH J -
FK506-BASED IMMUNOSUPPRESSION FOR PREVENTION OF GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER MATCHED UNRELATED DONOR (MUD) MARROW TRANSPLANTATION
BLOOD Volume: 84 Page(s): A341 - A341
11/15/1994 Authors: DEVINE SM; GELLER RB; HOLLAND HK; MORRIS LE; WINTON EF; HEFFNER LT; HILLYER CD; RODEY GE; DIX SP; OTOOLE K -
INTENSIVE TIME-SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR PATIENTS (PTS) WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) OR REFRACTORY RELAPSE ACUTE-LEUKEMIA - A POTENTIAL ROLE FOR GM-CSF TO ENHANCE RECRUITMENT
BLOOD Volume: 84 Page(s): A144 - A144
11/15/1994 Authors: GELLER RB; MORRIS L; WINTON EF; BRAY R; HEFFNER LT; HOLLAND KH; GILMORE C; DEVINE S; FARHI D; JAMISON K -
HIGH-DOSE BUSULFAN (BU), VP-16, CYTOXAN (CY) WITH MARROW RESCUE (BMT) FOR MULTIPLE-MYELOMA (MM)
BLOOD Volume: 82 Page(s): A578 - A578
11/15/1993 Authors: SEAY TE; DEVINE SM; GELLER RT; HEFFNER LT; HILLYER C; HOLLAND HK; RODEY GE; SARAL R; VOGLER WR; WINTON EF -
INTENSIVE TIMED SEQUENTIAL INDUCTION THERAPY WITH VP-16, MITOXANTRONE AND ARA-C FOR ADULT PATIENTS WITH ACUTE-LEUKEMIA
BLOOD Volume: 82 Page(s): A538 - A538
11/15/1993 Authors: GELLER RB; SIDHU GK; BRAY K; GILMORE C; KLEIN L; ROTHFIELD C; HEFFNER LT; HOLLAND HK; SEAY TE; WINTON EF -
ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE (AUC) WITH VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
BLOOD Volume: 82 Page(s): A418 - A418
11/15/1993 Authors: DIX SP; MULLINS RE; JERKUNICA I; DAVIDSON TG; GILMORE CE; YORK RC; LIN LS; DEVINE SM; GELLER RB; HEFFNER LT -
Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Blood Volume: 80 Page(s): 1423 - 1429
09/15/1992 Authors: Vogler WR; Berdel WE; Olson AC; Winton EF; Heffner LT; Gordon DS -
Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.
Bone Marrow Transplant Volume: 6 Page(s): 405 - 409
12/01/1990 Authors: Vogler WR; Winton EF; Heffner LT; Gordon DS; Sternberg P; Crocker I; Reynolds R; Dobbs CK -
Factors affecting survival in allogeneic bone marrow transplantation.
Am J Med Sci Volume: 297 Page(s): 300 - 308
05/01/1989 Authors: Vogler WR; Winton EF; Reynolds RC; Heffner LT; Gordon DS -
FACTORS AFFECTING SURVIVAL IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
EXPERIMENTAL HEMATOLOGY Volume: 16 Page(s): 495 - 495
07/01/1988 Authors: VOGLER WR; WINTON EF; HEFFNER LT; GORDON DS; REYNOLDS RC -
T-cell lymphoma following Hodgkin's disease.
Cancer Volume: 56 Page(s): 1191 - 1196
09/01/1985 Authors: Gowitt GT; Chan WC; Brynes RK; Heffner LT -
Treatment of cutaneous T cell lymphoma with cyclosporin A.
J Am Acad Dermatol Volume: 12 Page(s): 886 - 887
05/01/1985 Authors: Moreland AA; Robertson DB; Heffner LT -
TREATMENT OF CUTANEOUS T-CELL LYMPHOMA WITH CYCLOSPORIN-A
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Volume: 12 Page(s): 886 - 887
01/01/1985 Authors: MORELAND AA; ROBERTSON DB; HEFFNER LT -
Treatment of cutaneous T cell lymphoma with cyclosporin A
Journal of the American Academy of Dermatology Volume: 12 Page(s): 886 - 887
01/01/1985 Authors: Moreland AA; Robertson DB; Heffner LT -
Tcell lymphoma following Hodgkin's disease
Cancer Volume: 56 Page(s): 1191 - 1196
01/01/1985 Authors: Gowitt GT; Chan WC; Brynes RK; Heffner LT -
Prolymphocytic leukemia of helper cell phenotype: report of a case and review of the scientific literature.
Am J Clin Pathol Volume: 77 Page(s): 643 - 647
05/01/1982 Authors: Chan WC; Check IJ; Heffner LT; Gordon D; Whitsett C; Brynes RK -
CR-51 STUDIES VERIFY ANTI-PP1PK NOT DETECTABLE BY INVITRO CROSSMATCH AS CAUSE OF IMMEDIATE HEMOLYTIC TRANSFUSION REACTION
TRANSFUSION Volume: 22 Page(s): 407 - 407
01/01/1982 Authors: WHITSETT CF; DAFFIN LE; HEFFNER LT; SABO B; PIERCE JA -
The detection of inferior vena caval thrombosis with computed tomography.
Radiology Volume: 128 Page(s): 385 - 386
08/01/1978 Authors: Steele JR; Sones PJ; Heffner LT -
PHASE-1 STUDY OF 5FU - METHYL CCNU - METHOTREXATE WITH LEUCOVORIN IN ADVANCED ADENOCARCINOMA
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH Volume: 19 Page(s): 326 - 326
01/01/1978 Authors: NIXON DW; VOGLER WR; JACOBS J; HEFFNER LT; WINTON EF; GARRETT PR -
Transient peripheral plasmacytosis.
Am J Clin Pathol Volume: 62 Page(s): 8 - 15
07/01/1974 Authors: Moake JL; Landry PR; Oren ME; Sayer BL; Heffner LT -
A study of Hansen's disease in Ceylon.
South Med J Volume: 62 Page(s): 979 - 985
08/01/1969 Authors: Heffner LT